Drug intelligence / Profile preview

anti-IL-26 monoclonal antibody

Development stage: Preclinical
Lead developer: Signal26 Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Signal26 Biotherapeutics is developing a monoclonal antibody targeting interleukin-26 (IL-26) for the treatment of chronic inflammatory diseases. Developed in collaboration with the Centre Hospitalier Universitaire Vaudois (CHUV), this therapeutic agent is designed to bind and neutralize IL-26, a Th17 cytokine implicated in the pathogenesis of several autoimmune conditions. By blocking IL-26's interaction with DNA and its subsequent activation of innate immune cells, the antibody prevents downstream interferon-driven inflammatory responses. The primary clinical focus is palmoplantar pustular psoriasis (PPPP), a condition currently lacking approved treatments, with additional research exploring its potential in rheumatoid arthritis and inflammatory bowel disease.

Other names: anti-IL-26 antibodyanti-IL26 antibodyanti-IL 26 antibodyanti-IL-26 mAbanti-IL26 mAbanti-IL 26 mAb

Targets

IL26 (Interleukin-26)

Beyond the preview

Go deeper on anti-IL-26 monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-IL-26 monoclonal antibody.

Explore the full profile